Recombinant epidermal growth factor biosimilar (Elea)

重组人表皮生长因子生物类似药 (Elea)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant epidermal growth factor biosimilar (Elea)
Drug Alias Name重组人表皮生长因子生物仿制药 (Elea)r-hu-EGF
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 agonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBurnsDiabetic Foot
Global Approved IndicationsBurnsDiabetic Foot
Approved Indications in ChinaN/A
Original Approved Country/TerritoryArgentina
Original Approved Date2015/01/01
Country/TerritoryArgentina
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesElea
China Registration ClassN/A

Develop Information

Active CompaniesElea
Inactive CompaniesN/A
Active IndicationsBurnsDiabetic Foot
Inactive IndicationsN/A

Other Information

ATC CodeD03
Related LinksN/A